The present study was conducted to evaluate the efficacy and safety of the novel “BRICS” sequential therapeutic regimen in patients with EGFR/ALK wild-type, PD-L1-negative advanced NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.